Teriparatide News and Research

RSS

Computer model for osteoporosis diagnostics

Osteoporosis, a common age-related disease, is being investigated by a group of biomechanical engineers at Vienna University of Technology (TU Vienna).

23 Jan 2008

Effectiveness and risks of six bisphosphonates for osteoporosis

Many medications reduce the risk of bone fractures in people with osteoporosis, but the most commonly used drugs - bisphosphonates - have not been proven more effective than alternatives, according to a new report funded by the Agency for Healthcare Research and Quality (AHRQ), part of the U.S. Department of Health and Human Services.

18 Dec 2007

Lilly to extend patient assistance programs for Medicare patients

Eli Lilly and Company has announced that it will be extending its existing patient assistance program, LillyAnswers, through the end of this year to qualifying patients currently participating in the program, to help bridge the gap in coverage for people who need Lilly medicines, but are not yet enrolled in Medicare Part D.

11 May 2006

Calcium crucial to benefits of osteoporosis drugs

Although an increasing number of people are taking powerful new prescription drugs to treat osteoporosis, chances are the majority of patients are not getting the greatest effect from these medicines because they do not have an adequate calcium and vitamin D intake, according to a paper published in the March 2005 issue of The Journal of Women's Health.

23 Mar 2005

$Analysis shows Teriparatide reduces fracture risk independent of bone turnover$

Analysis shows Teriparatide reduces fracture risk independent of bone turnover

Data presented yesterday at the 26th annual meeting of the American Society for Bone and Mineral Research (ASBMR) show that the ability of teriparatide to prevent fractures remained consistent regardless of pretreatment bone turnover status.

5 Oct 2004

Early patient response to Forteo in postmenopausal women with osteoporosis

Changes in markers of bone remodeling after one month of treatment with FORTEO® (teriparatide [rDNA origin] injection) may provide important early evidence of treatment response, according to new data presented today at the 86th Annual Meeting of The Endocrine Society (ENDO).

17 Jun 2004